 Biocept Inc NASDAQ:BIOC FRA:B003 started 2021 on a high with a profitable first quarter on revenue of 17.8 million, driven primarily by its coronavirus COVID-19 tests. For the period ended March 31, 2020, the San Diego-based company, which develops molecular diagnostic assays, posted revenue of 17.8 million, compared with 1.4 million for the first quarter of 2020. 